-
公开(公告)号:US20240082395A1
公开(公告)日:2024-03-14
申请号:US18454286
申请日:2023-08-23
Applicant: Alector LLC
Inventor: Andrew Pincetic , Arnon Rosenthal , Seung-Joo Lee
IPC: A61K39/395 , A61P31/00 , A61P35/00 , C07K16/28
CPC classification number: A61K39/39558 , A61P31/00 , A61P35/00 , C07K16/2803 , C07K2317/24 , C07K2317/732 , C07K2317/75 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.
-
公开(公告)号:US11779642B2
公开(公告)日:2023-10-10
申请号:US16463062
申请日:2017-12-08
Applicant: Alector LLC
Inventor: Andrew Pincetic , Arnon Rosenthal , Seung-Joo Lee
IPC: A61K39/395 , A61P31/00 , A61P35/00 , C07K16/28
CPC classification number: A61K39/39558 , A61P31/00 , A61P35/00 , C07K16/2803 , C07K2317/24 , C07K2317/732 , C07K2317/75 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.
-
公开(公告)号:US11667699B2
公开(公告)日:2023-06-06
申请号:US16943123
申请日:2020-07-30
Applicant: Alector LLC
Inventor: Jeonghoon Sun , Wei-Hsien Ho , Muhammad A. Alhawagri , Philip Ling Kong , Herve Rhinn , Hua Long , Karpagam Srinivasan , Ananya Mitra , Daniel P. Bermingham , Klaus-Dieter Heger , Santiago Viveros Salazar , Francesca Cignarella , Ilaria Tassi , Tina Schwabe , Angie Grace Yee , Arnon Rosenthal
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/732 , C07K2317/734 , C07K2317/92
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20230035072A1
公开(公告)日:2023-02-02
申请号:US17784579
申请日:2020-12-11
Applicant: Alector LLC
Inventor: Robert PAUL , Michael F. WARD , Hua LONG , Shiao-Ping LU , Omer Rizwan SIDDIQUI , Arnon ROSENTHAL
Abstract: The present disclosure is generally directed to antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics. The present disclosure is further directed to the methods of treating and/or delaying the progression of a disease or injury in an individual by administering such antibodies.
-
公开(公告)号:US11472877B2
公开(公告)日:2022-10-18
申请号:US16078965
申请日:2017-03-03
Applicant: Alector LLC
Inventor: Andrew Pincetic , Arnon Rosenthal , Helen Lam , Francesca Avogadri-Connors , Seung-Joo Lee
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20220289844A1
公开(公告)日:2022-09-15
申请号:US17707637
申请日:2022-03-29
Applicant: Alector LLC
Inventor: Andrew Pincetic , Wei-Hsien Ho , Patricia Culp , Arnon Rosenthal
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20220185898A1
公开(公告)日:2022-06-16
申请号:US17534270
申请日:2021-11-23
Applicant: Alector LLC
Inventor: Arnon ROSENTHAL , Tina SCHWABE , Michael KURNELLAS , Robert PEJCHAL , Anthony B. COOPER
IPC: C07K16/28 , A61K31/7088
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US11359014B2
公开(公告)日:2022-06-14
申请号:US16614302
申请日:2018-05-15
Applicant: Alector LLC
Inventor: Kate Monroe , Helen Lam , Patricia Culp , Arnon Rosenthal
IPC: C07K16/28 , A61P37/00 , A61P25/28 , A61P31/04 , A61P25/00 , A61P25/08 , A61P29/00 , A61P35/00 , A61K39/00
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20210403540A1
公开(公告)日:2021-12-30
申请号:US17156153
申请日:2021-01-22
Applicant: ALECTOR LLC
Inventor: Arnon ROSENTHAL
Abstract: The present disclosure generally relates to antigen-binding proteins (ABPs) that specifically bind to apolipoprotein E (ApoE), compositions comprising such ABPs, methods of using such ABPs, and methods of making such ABPs. In some embodiments, the ABPs provided herein bind lipidated ApoE4. In some embodiments, the lipidated ApoE4 is within a lipoprotein particle, and the ABPs therefore bind to a lipoprotein particle comprising ApoE4. Any suitable ABP may be used. In some embodiments, the ABP is an antibody. In some embodiments, the ABP is an alternative scaffold. The ABPs provided herein may be used for the prevention or treatment of any disease, condition or disorder associated with ApoE4 expression.
-
公开(公告)号:US20210277113A1
公开(公告)日:2021-09-09
申请号:US17256508
申请日:2019-06-28
Applicant: Alector LLC
Inventor: Andrew Pincetic , Patricia Culp , Arnon Rosenthal
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPβ1 polypeptide, e.g., a human SIRPβ1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
-
-
-
-
-
-
-
-